필터
“5133” 에 대한 검색 결과 11 건
정렬 기준:
알파벳순 (A-Z)
베스트셀러
huPD-1
제품 ID:
C001524
계통(Strain):
C57BL/6JCya
상태:
설명:
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 costimulatory receptor family. It is an inhibitory receptor expressed on activated T cells and plays a role in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in a variety of tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in the defense against autoimmune diseases and has inhibitory effects on antitumor and antimicrobial immunity [1]. PD-1 binds to programmed death ligands 1 and 2 (PD-L1 and PD-L2) to inhibit T cell activation, reduce the production of corresponding cytokines, and regulate T cell survival [2]. Drugs targeting this pathway can reactivate T cells to activate antitumor immune responses [3].
This strain is a genetically modified mouse model in which the gene encoding the mouse PD-1 protein is humanized, resulting in the expression of human PD-1 protein in mice. This model can be used for research in drug development, efficacy and safety evaluation, tumor immunotherapy evaluation, and immune system mechanisms related to PD-1.
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 costimulatory receptor family. It is an inhibitory receptor expressed on activated T cells and plays a role in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in a variety of tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in the defense against autoimmune diseases and has inhibitory effects on antitumor and antimicrobial immunity [1]. PD-1 binds to programmed death ligands 1 and 2 (PD-L1 and PD-L2) to inhibit T cell activation, reduce the production of corresponding cytokines, and regulate T cell survival [2]. Drugs targeting this pathway can reactivate T cells to activate antitumor immune responses [3].
This strain is a genetically modified mouse model in which the gene encoding the mouse PD-1 protein is humanized, resulting in the expression of human PD-1 protein in mice. This model can be used for research in drug development, efficacy and safety evaluation, tumor immunotherapy evaluation, and immune system mechanisms related to PD-1.
huPD-1/huCD19
제품 ID:
C002040
계통(Strain):
C57BL/6J;6NCya
상태:
설명:
The huPD-1/huCD19 mouse is a dual-gene humanized model obtained by crossing the huPD-1 mouse (Catalog No.: C001524) with the huCD19 mouse (Catalog No.: C001731). This model is suitable for studying drug screening, pharmacodynamic evaluation, safety assessment, tumor immunotherapy, and the underlying mechanisms of the immune system related to PD-1/CD19.
The huPD-1/huCD19 mouse is a dual-gene humanized model obtained by crossing the huPD-1 mouse (Catalog No.: C001524) with the huCD19 mouse (Catalog No.: C001731). This model is suitable for studying drug screening, pharmacodynamic evaluation, safety assessment, tumor immunotherapy, and the underlying mechanisms of the immune system related to PD-1/CD19.
huPD-1/huFcRn
제품 ID:
C002041
계통(Strain):
C57BL/6J;6NCya
상태:
설명:
The huPD-1/huFcRn mice are a dual-gene humanized model obtained by mating huPD-1 mice (Catalog Number: C001524) with huFcRn(FCGRT) mice (Catalog Number: C001701). This model is applicable to the screening of human IgG antibody drug candidates, as well as the evaluation of pharmacology, pharmacodynamics, and pharmacokinetics. It serves as a valuable tool for advancing research in tumor immunotherapy and the mechanisms of the immune system.
The huPD-1/huFcRn mice are a dual-gene humanized model obtained by mating huPD-1 mice (Catalog Number: C001524) with huFcRn(FCGRT) mice (Catalog Number: C001701). This model is applicable to the screening of human IgG antibody drug candidates, as well as the evaluation of pharmacology, pharmacodynamics, and pharmacokinetics. It serves as a valuable tool for advancing research in tumor immunotherapy and the mechanisms of the immune system.
B6-hPD-1/hVEGFA
제품 ID:
C001598
계통(Strain):
C57BL/6JCya
상태:
설명:
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 costimulatory receptor family. It is an inhibitory receptor expressed on activated T cells and plays a role in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in a variety of tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in the defense against autoimmune diseases and has inhibitory effects on antitumor and antimicrobial immunity [1]. PD-1 binds to programmed death ligands 1 and 2 (PD-L1 and PD-L2) to inhibit T cell activation, reduce the production of corresponding cytokines, and regulate T cell survival [2]. Drugs targeting this pathway can reactivate T cells to activate antitumor immune responses [3].
The Vascular Endothelial Growth Factor (VEGF) family is a group of particular endothelial growth factors intimately associated with angiogenesis. These factors promote increased vascular permeability, extracellular matrix degeneration, vascular endothelial cell migration and proliferation, and are capable of stimulating angiogenesis and increasing the permeability of existing vessels. As such, they play a pivotal role in normal vascular development and wound healing. The VEGF family comprises VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and PLGF [4]. Of these, VEGFA is the most commonly targeted in research related to neovascular ophthalmic diseases due to its crucial role in the proliferation, migration, and formation of endothelial cell microvessels [5]. Overexpression of VEGFA in the eye can result in abnormal vascular growth and leakage, leading to various ophthalmic diseases such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and corneal neovascularization [5-6]. The progression of solid tumors depends on vascularization and angiogenesis within malignant tissues, with VEGFA playing a crucial role among various pro-angiogenic factors. The VEGFA gene is upregulated in many known tumors, correlating with tumor staging and progression. Blocking VEGFA may lead to vascular network regression, inhibiting tumor growth [7]. Thus, VEGFA is an important target for anti-angiogenic cancer therapies.
The B6-hPD-1/hVEGFA mouse is a humanized model obtained by crossbreeding hPD-1 mice (Catalog No. C001524) with B6-hVEGFA mice (Catalog No. C001555). This model can be used for research in drug development, efficacy and safety evaluation, tumor immunotherapy evaluation, and immune system mechanisms related to human PD-1/VEGFA.
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 costimulatory receptor family. It is an inhibitory receptor expressed on activated T cells and plays a role in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in a variety of tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in the defense against autoimmune diseases and has inhibitory effects on antitumor and antimicrobial immunity [1]. PD-1 binds to programmed death ligands 1 and 2 (PD-L1 and PD-L2) to inhibit T cell activation, reduce the production of corresponding cytokines, and regulate T cell survival [2]. Drugs targeting this pathway can reactivate T cells to activate antitumor immune responses [3].
The Vascular Endothelial Growth Factor (VEGF) family is a group of particular endothelial growth factors intimately associated with angiogenesis. These factors promote increased vascular permeability, extracellular matrix degeneration, vascular endothelial cell migration and proliferation, and are capable of stimulating angiogenesis and increasing the permeability of existing vessels. As such, they play a pivotal role in normal vascular development and wound healing. The VEGF family comprises VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and PLGF [4]. Of these, VEGFA is the most commonly targeted in research related to neovascular ophthalmic diseases due to its crucial role in the proliferation, migration, and formation of endothelial cell microvessels [5]. Overexpression of VEGFA in the eye can result in abnormal vascular growth and leakage, leading to various ophthalmic diseases such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and corneal neovascularization [5-6]. The progression of solid tumors depends on vascularization and angiogenesis within malignant tissues, with VEGFA playing a crucial role among various pro-angiogenic factors. The VEGFA gene is upregulated in many known tumors, correlating with tumor staging and progression. Blocking VEGFA may lead to vascular network regression, inhibiting tumor growth [7]. Thus, VEGFA is an important target for anti-angiogenic cancer therapies.
The B6-hPD-1/hVEGFA mouse is a humanized model obtained by crossbreeding hPD-1 mice (Catalog No. C001524) with B6-hVEGFA mice (Catalog No. C001555). This model can be used for research in drug development, efficacy and safety evaluation, tumor immunotherapy evaluation, and immune system mechanisms related to human PD-1/VEGFA.
B6-hPD-1/hPD-L1
제품 ID:
I001202
계통(Strain):
C57BL/6Cya
상태:
설명:
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 costimulatory receptor family. It is an inhibitory receptor expressed on activated T cells and plays a role in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in a variety of tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in the defense against autoimmune diseases and has inhibitory effects on antitumor and antimicrobial immunity [1].
Programmed cell death 1 ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7H1), is an immune inhibitory receptor ligand. PD-L1 is a type I transmembrane protein with immunoglobulin V-like (IgV) and C-like (IgC) structural domains and is expressed by hematopoietic and non-hematopoietic cells, including T cells, B cells, and various types of tumor cells [2]. PD-L1 can bind to the PD-1 on the surface of CD8+ T cells, inhibiting the activity of CD8+ T cells. This interaction can prevent the immune system from damaging normal tissues, but it can also be used by tumor cells to escape immune surveillance. Monoclonal antibodies that competitively bind to PD-L1 can relieve the immune function inhibition mediated by the binding of PD-1 and PD-L1. This can reactivate CD8+ T cells, triggering the human body's anti-tumor immune response [3]. Therefore, developing of antibody drugs targeting PD-1 and PD-L1 is a hot area in tumor immunotherapy [3-5].
B6-hPD-1/hPDL1 mice are PD-1 and CD274 double humanized mouse models obtained by mating PD-1 humanized mouse models with CD274 humanized mouse models. They express human PD-1 and CD274 genomic sequences under the control of mouse promoters. This model is a valuable tool for studying cancer immunotherapy. In addition, this model also provides a powerful preclinical research platform for evaluating the efficacy and mechanism of therapeutic drugs targeting PD-1 and PD-L1.
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 costimulatory receptor family. It is an inhibitory receptor expressed on activated T cells and plays a role in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in a variety of tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in the defense against autoimmune diseases and has inhibitory effects on antitumor and antimicrobial immunity [1].
Programmed cell death 1 ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7H1), is an immune inhibitory receptor ligand. PD-L1 is a type I transmembrane protein with immunoglobulin V-like (IgV) and C-like (IgC) structural domains and is expressed by hematopoietic and non-hematopoietic cells, including T cells, B cells, and various types of tumor cells [2]. PD-L1 can bind to the PD-1 on the surface of CD8+ T cells, inhibiting the activity of CD8+ T cells. This interaction can prevent the immune system from damaging normal tissues, but it can also be used by tumor cells to escape immune surveillance. Monoclonal antibodies that competitively bind to PD-L1 can relieve the immune function inhibition mediated by the binding of PD-1 and PD-L1. This can reactivate CD8+ T cells, triggering the human body's anti-tumor immune response [3]. Therefore, developing of antibody drugs targeting PD-1 and PD-L1 is a hot area in tumor immunotherapy [3-5].
B6-hPD-1/hPDL1 mice are PD-1 and CD274 double humanized mouse models obtained by mating PD-1 humanized mouse models with CD274 humanized mouse models. They express human PD-1 and CD274 genomic sequences under the control of mouse promoters. This model is a valuable tool for studying cancer immunotherapy. In addition, this model also provides a powerful preclinical research platform for evaluating the efficacy and mechanism of therapeutic drugs targeting PD-1 and PD-L1.
B6-hPD-1/hCTLA4
제품 ID:
I001143
계통(Strain):
C57BL/6NCya
상태:
설명:
PD-1 and CTLA-4 are checkpoint receptors that critically modulate T cell immunity. The genes PDCD1 and CTLA4 encode PD-1 and CTLA-4 respectively, with CTLA4 expression largely restricted to T cells, while PDCD1 is evident in activated T cells, B cells, and myeloid populations [1]. These transmembrane proteins function as key negative regulators of T cell activation [2]. CTLA-4 primarily operates in lymphoid tissues during early immune responses to restrain T cell proliferation, whereas PD-1 predominantly acts in peripheral tissues during the effector phase to dampen T cell activity and limit immunopathology, particularly in chronically stimulated or ‘exhausted’ T cells [2-3]. Aberrant regulation of PD-1 and CTLA-4 is implicated in the pathogenesis of cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma, as well as chronic viral infections such as hepatitis B and C [1][4]. Clinically, monoclonal antibodies targeting CTLA-4 (e.g., ipilimumab) and PD-1 (e.g., nivolumab, pembrolizumab) are established immunotherapeutic agents that enhance anti-tumor responses. By blocking these negative signaling pathways, these monoclonal antibodies restore the anti-tumor activity of T cells, significantly enhancing anti-tumor responses [1-2]. These drug applications have not only improved the treatment outcomes for various cancers but also offer new strategies for the treatment of chronic viral infections.
B6-hPD-1/hCTLA4 mouse is a dual humanized model of PD1 and CTLA4 constructed by humanizing the mouse Pdcd1 gene based on the CTLA4 humanized mouse model (Catalog No. C001413), due to the fact that the mouse Pdcd1 gene and Ctla4 gene are on the same chromosome. These mice express human CTLA4 and PDCD1 genomic sequences under the control of mouse promoters. This model is capable of reproducing the human PD-1/CTLA4 signaling pathway and is a valuable tool for studying cancers and chronic viral infections. Furthermore, this model provides a powerful preclinical research platform for evaluating the efficacy and mechanism of therapeutic drugs targeting the PD-1/CTLA4 signaling pathway.
PD-1 and CTLA-4 are checkpoint receptors that critically modulate T cell immunity. The genes PDCD1 and CTLA4 encode PD-1 and CTLA-4 respectively, with CTLA4 expression largely restricted to T cells, while PDCD1 is evident in activated T cells, B cells, and myeloid populations [1]. These transmembrane proteins function as key negative regulators of T cell activation [2]. CTLA-4 primarily operates in lymphoid tissues during early immune responses to restrain T cell proliferation, whereas PD-1 predominantly acts in peripheral tissues during the effector phase to dampen T cell activity and limit immunopathology, particularly in chronically stimulated or ‘exhausted’ T cells [2-3]. Aberrant regulation of PD-1 and CTLA-4 is implicated in the pathogenesis of cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma, as well as chronic viral infections such as hepatitis B and C [1][4]. Clinically, monoclonal antibodies targeting CTLA-4 (e.g., ipilimumab) and PD-1 (e.g., nivolumab, pembrolizumab) are established immunotherapeutic agents that enhance anti-tumor responses. By blocking these negative signaling pathways, these monoclonal antibodies restore the anti-tumor activity of T cells, significantly enhancing anti-tumor responses [1-2]. These drug applications have not only improved the treatment outcomes for various cancers but also offer new strategies for the treatment of chronic viral infections.
B6-hPD-1/hCTLA4 mouse is a dual humanized model of PD1 and CTLA4 constructed by humanizing the mouse Pdcd1 gene based on the CTLA4 humanized mouse model (Catalog No. C001413), due to the fact that the mouse Pdcd1 gene and Ctla4 gene are on the same chromosome. These mice express human CTLA4 and PDCD1 genomic sequences under the control of mouse promoters. This model is capable of reproducing the human PD-1/CTLA4 signaling pathway and is a valuable tool for studying cancers and chronic viral infections. Furthermore, this model provides a powerful preclinical research platform for evaluating the efficacy and mechanism of therapeutic drugs targeting the PD-1/CTLA4 signaling pathway.
huPD-1/huTNF(B6;D1)
제품 ID:
C002037
계통(Strain):
C57BL/6J;DBA/1Cya
상태:
설명:
The huPD-1/huTNF(B6;D1) mice are a dual-gene humanized model obtained by mating huPD-1 mice (Catalog number: C001524) with huTNF(DBA/1) mice (Catalog number: C001587). This model is suitable for research on drug screening, efficacy and safety evaluation, immunotherapy, and immune system mechanisms related to PD-1 and TNF.
The huPD-1/huTNF(B6;D1) mice are a dual-gene humanized model obtained by mating huPD-1 mice (Catalog number: C001524) with huTNF(DBA/1) mice (Catalog number: C001587). This model is suitable for research on drug screening, efficacy and safety evaluation, immunotherapy, and immune system mechanisms related to PD-1 and TNF.
huPD-1/hPD-L1/huCD19
제품 ID:
C002087
계통(Strain):
C57BL/6J;6NCya
상태:
설명:
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 family of costimulatory receptor proteins. It is expressed on activated T cells and functions as an immunosuppressive receptor involved in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in various tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in immune tolerance and suppresses antitumor and antimicrobial immune responses [1].
PDL1, also known as programmed cell death 1 ligand 1 (PD-L1), cluster of differentiation 274 (CD274), or B7 homolog 1 (B7-H1), encodes an immunosuppressive receptor ligand mainly expressed by hematopoietic and non-hematopoietic cells, including T cells, B cells, and various tumor cells [2]. PD-L1 is a type I transmembrane protein containing immunoglobulin V-like (IgV) and C-like (IgC) domains. PD-L1 interacts with the PD-1 receptor expressed on T cells, thereby inhibiting T cell activation and effector function. This interaction prevents excessive immune responses against normal tissues but can also be exploited by tumor cells to evade immune surveillance. Monoclonal antibodies targeting PD-L1 can disrupt the interaction between PD-1 and PD-L1, reverse PD-1/PD-L1-mediated immune suppression, reactivate T cells, and initiate antitumor immune responses [3].
The CD19 gene encodes a member of the immunoglobulin superfamily and serves as a key co-receptor in the B cell receptor (BCR) signaling pathway, playing an essential role in B cell development, activation, and differentiation. CD19 is a pan-B cell marker that is specifically expressed in the B cell lineage and remains stably expressed throughout B cell development, from pre-B cells to mature B cells and memory B cells. CD19 acts as a positive regulator of BCR signaling. The CD19 protein forms a B cell-specific signaling complex with CD21 (complement receptor type 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B cell activation [4].
The huPD-1/hPD-L1/huCD19 mouse is a triple-gene humanized model generated by crossing the hPDL1-V(2) mouse (Product No.: C001235), the huPD-1 mouse (Product No.: C001524), and the huCD19 mouse (Product No.: C001731). This model can be used for pharmacodynamic evaluation, mechanism of action studies, and combination therapeutic strategy development of anti-CD19 therapeutics and PD-1/PD-L1 immune checkpoint inhibitors. It supports the evaluation of combination therapies involving anti-CD19 CAR-T cells, bispecific antibodies, and immune checkpoint inhibitors, as well as studies of B cell–T cell interactions and tumor immune microenvironment mechanisms. This model provides a preclinical research platform for developing innovative immunotherapies for B-cell malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).
Programmed cell death protein 1 (PDCD1/PD-1) is a member of the B7-CD28 family of costimulatory receptor proteins. It is expressed on activated T cells and functions as an immunosuppressive receptor involved in regulating the function of effector T cells, including CD8+ T cells, and promoting the differentiation of CD4+ T cells into regulatory T cells. PD-1 is expressed in various tumors and plays an important role in antitumor immunity. In addition, PD-1 is involved in immune tolerance and suppresses antitumor and antimicrobial immune responses [1].
PDL1, also known as programmed cell death 1 ligand 1 (PD-L1), cluster of differentiation 274 (CD274), or B7 homolog 1 (B7-H1), encodes an immunosuppressive receptor ligand mainly expressed by hematopoietic and non-hematopoietic cells, including T cells, B cells, and various tumor cells [2]. PD-L1 is a type I transmembrane protein containing immunoglobulin V-like (IgV) and C-like (IgC) domains. PD-L1 interacts with the PD-1 receptor expressed on T cells, thereby inhibiting T cell activation and effector function. This interaction prevents excessive immune responses against normal tissues but can also be exploited by tumor cells to evade immune surveillance. Monoclonal antibodies targeting PD-L1 can disrupt the interaction between PD-1 and PD-L1, reverse PD-1/PD-L1-mediated immune suppression, reactivate T cells, and initiate antitumor immune responses [3].
The CD19 gene encodes a member of the immunoglobulin superfamily and serves as a key co-receptor in the B cell receptor (BCR) signaling pathway, playing an essential role in B cell development, activation, and differentiation. CD19 is a pan-B cell marker that is specifically expressed in the B cell lineage and remains stably expressed throughout B cell development, from pre-B cells to mature B cells and memory B cells. CD19 acts as a positive regulator of BCR signaling. The CD19 protein forms a B cell-specific signaling complex with CD21 (complement receptor type 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B cell activation [4].
The huPD-1/hPD-L1/huCD19 mouse is a triple-gene humanized model generated by crossing the hPDL1-V(2) mouse (Product No.: C001235), the huPD-1 mouse (Product No.: C001524), and the huCD19 mouse (Product No.: C001731). This model can be used for pharmacodynamic evaluation, mechanism of action studies, and combination therapeutic strategy development of anti-CD19 therapeutics and PD-1/PD-L1 immune checkpoint inhibitors. It supports the evaluation of combination therapies involving anti-CD19 CAR-T cells, bispecific antibodies, and immune checkpoint inhibitors, as well as studies of B cell–T cell interactions and tumor immune microenvironment mechanisms. This model provides a preclinical research platform for developing innovative immunotherapies for B-cell malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).
Ube2d1-KO
제품 ID:
S-KO-05133
계통(Strain):
C57BL/6JCya
상태:
설명:
Ube2d1 is located on chromosome 10 of mice. Nuclease Technology will be used to design sgRNA; Ube2d1 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Ube2d1 is located on chromosome 10 of mice. Nuclease Technology will be used to design sgRNA; Ube2d1 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Ighmbp2-flox
제품 ID:
S-CKO-05133
계통(Strain):
C57BL/6JCya
상태:
설명:
Ighmbp2 is located on chromosome 19 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Ighmbp2 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Ighmbp2 is located on chromosome 19 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Ighmbp2 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Items: 1 to 10 of 11
1
2
더보기